Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dynamic impact of bivalent COVID-19 vaccine boosters on systemic and mucosal antibody and T cell immunity.

Scientific reports·2025
Same author

Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial.

Nature communications·2025
Same author

Antibody testing to predict SARS-CoV-2 risk in immunocompromised people.

Lancet (London, England)·2025
Same author

COVID-19 vaccines are effective at preventing symptomatic and severe infection among healthcare workers: A clinical review.

Vaccine: X·2024
Same author

Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults.

The Journal of infectious diseases·2024
Same author

Macrophage transplantation rescues RNASET2-deficient leukodystrophy by replacing deficient microglia in a zebrafish model.

Proceedings of the National Academy of Sciences of the United States of America·2024

Related Experiment Video

Updated: May 18, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Improving targeted screening for hepatitis C in the UK

Christopher J A Duncan, Ewen Stewart, Ray Fox

    BMJ (Clinical Research Ed.)
    |October 5, 2012
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
    09:35

    Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

    Published on: February 1, 2017

    Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
    05:55

    Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

    Published on: December 21, 2019

    Related Experiment Videos

    Last Updated: May 18, 2026

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
    11:34

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

    Published on: May 10, 2022

    Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
    09:35

    Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

    Published on: February 1, 2017

    Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
    05:55

    Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

    Published on: December 21, 2019